In this issue:
Factors associated with early progression after ide-cel for RRMM
MyCARe model identifies patients at risk of early relapse after CAR T-cell therapy
Stem cell boost improves persistent ICAHT after CAR T-cell therapy
Prognostic factors in real-world patients receiving bortezomib-based induction
Pre-transplant MRD-positivity may portend inferior outcomes
Early post-transplant M-protein immune reconstitution a marker for favourable outcomes
Is there any benefit to upfront tandem autologous-allogeneic transplant?
Novel model may improve prediction of SMM in individuals with MGUS
IKEMA: significant benefit to isatuximab triplet in 1q21+ patients with RRMM
Repurposed HIV medicine nelfinavir has no activity in myeloma
Please login below to download this issue (PDF)